Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

9.010 -0.680 (-7.02%)
Streaming Delayed Price Updated: 3:02 PM EDT, Aug 9, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 740,144
Open 9.650
Bid (Size) 9.010 (3)
Ask (Size) 9.030 (5)
Prev. Close 9.690
Today's Range 8.930 - 9.770
52wk Range 5.061 - 14.34
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga

Performance

YTD
+28.35%
+28.35%
1 Month
-32.15%
-32.15%
3 Month
-11.84%
-11.84%
6 Month
+11.58%
+11.58%
1 Year
-21.79%
-21.79%

More News

Read More
Evolus Reports Second Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus's Earnings: A Preview
Via Benzinga
Needham Is Bullish On This Botox Equivalent Aesthetics Company
Via Benzinga
Recap: Evolus Q4 Earnings
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Via Benzinga
Recap: Evolus Q2 Earnings
Via Benzinga
Evolus to Report Second Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
From Evolus
Via Business Wire
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Via Benzinga
Evolus's Return On Capital Employed Overview
Via Benzinga
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
From Evolus
Via Business Wire
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
From Evolus
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Via Benzinga
Evolus to Participate in the H.C. Wainwright Global Investment Conference
From Evolus
Via Business Wire
Evolus: Q1 Earnings Insights
Via Benzinga
Evolus Reports First Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
Evolus to Report First Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Evolus's Return On Capital Employed Insights
Via Benzinga
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.